European ScreeningPort selects IDBS’ ActivityBase
Use of ActivityBase, which is used by pharma companies, helps fulfil European ScreeningPort’s goal of providing academia with the services needed to transfer their research to industry.
Sheraz Gul, vice president and head of biology at European ScreeningPort, explained that ActivityBase ensures appropriate data integrity and its use in industry gives the organisation credibility.
European ScreeningPort will use the system to capture, visualise, analyse, quality check and verify data generated by plate-based screening. IDBS believes performing these tasks in the same environment streamlines workflow and optimises productivity.
Neil Kipling, founder and CEO of IDBS, added: "Working with European ScreeningPort, IDBS is providing a platform for effective scientific collaboration between academic research and the pharmaceutical industry, enabling a unique network of partners to combine their scientific knowledge, technical expertise and industry experience."
European ScreeningPort’s development
Addition of the technology is the latest step in the growth of Germany-based European ScreeningPort, which was established in 2007 to provide academic institutes with pharma industry standard services.
Evotec was involved in setting up the public-private partnership. Since launching European ScreeningPort has provided academic partners, including Helmholtz Research Society and Max Planck organisations, with an array of small molecule screening services.
These give organisations access to automated molecular screening platforms, bioinformatics knowledge, chemical and biological infrastructure and staff with substantial pharmaceutical industry experience.
